Powerful treatment.
Purposeful support.
Alcon offers support to help you get the most out of your ROCKLATAN® treatment.
How does ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% work?
Elevated IOP may result in glaucoma
For people with open-angle glaucoma, fluid in the eye (called aqueous humor) does not drain properly. This elevates the pressure in the eye.
How can ROCKLATAN® help?
ROCKLATAN® is a combination of 2 prescription medicines to reduce high eye pressure in patients with open-angle glaucoma or ocular hypertension.
- ROCKLATAN® contains 2 medications in a single drop, which each work to lower IOP more than the single medication alone
- ROCKLATAN® increases your eye’s ability to drain the aqueous humor in 2 different ways, which can help reduce the pressure within the eye
Enroll today to get support and savings for your ROCKLATAN® treatment
IOP=Intraocular pressure.
Savings & Support
Whether you're starting treatment or currently being treated, Alcon is committed to supporting patient affordability by providing support and savings for its treatments.
Enroll and download the Alcon Savings Copay Card for savings on your ROCKLATAN® prescription (for eligible, commercially insured patients)
Resources
Glaucoma Glossary
Learn some of the common terms you may see when reading about glaucoma.
Guide to Open-Angle Glaucoma
A short guide to help you better understand your condition.
Learn more about open-angle glaucoma
How do I use ROCKLATAN®?
ROCKLATAN® should be taken once daily in the evening
- The recommended dose for ROCKLATAN® is one drop in the affected eye(s) once daily in the evening
- If you miss a dose of ROCKLATAN®, you should continue with your next dose the following evening
- If more than 1 eye drop is being used, the drugs should be administered at least 5 minutes apart
- Contact lenses should be removed prior to the administration of ROCKLATAN® and may be reinserted 15 minutes after administration
- Avoid touching the tip of the container to the eyes, fingers, or any surface to avoid contamination of the solution
Storing ROCKLATAN®
- ROCKLATAN® should be protected from light. Keep the ROCKLATAN® bottle in the refrigerator (36 °F to 46 °F) until opened
- After opening, ROCKLATAN® may be kept at 36 °F to 77 °F for up to 6 weeks
- If after opening, ROCKLATAN® is kept refrigerated at 36 °F to 46 °F, then the product can be used until the expiration date stamped on the bottle
INDICATION
- What is ROCKLATAN®?
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription eye drop that contains two medicines to reduce high eye pressure (intraocular pressure, or IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
- ROCKLATAN® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as ROCKLATAN® is administered, and eye color changes are likely to be permanent. Eyelash and eyelid changes may be reversible after discontinuation of ROCKLATAN®.
- Avoid allowing the tip of the bottle to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solution.
- If you develop another ocular condition (e.g., trauma or infection, or decreased vision with or without eye pain), have ocular surgery, or develop any ocular side effects, particularly conjunctivitis and eyelid reactions, you should immediately seek your healthcare provider’s advice about continuing to use ROCKLATAN®.
- The preservative in ROCKLATAN®, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of ROCKLATAN®, but may be reinserted 15 minutes after instillation.
- If you are using more than one eyedrop, the drugs should be administered at least 5 minutes apart.
- The most common side effect of ROCKLATAN® in clinical trials was red eyes (59% of patients). Five percent of patients stopped taking ROCKLATAN® due to red eyes. Other common side effects were: instillation site pain (20%), small deposits on the outer surface of the eye (15%), and broken blood vessels on the white of the eye (11%).
For additional information about ROCKLATAN®, talk to your healthcare provider and click here to see the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.